4 Efforts to vaccinate against coronavirus are likely to pay off

The long-awaited coronavirus vaccine is likely to be available for emergency use by mid-December. Many commander-in-chief of the pharmaceutical industry, as well as biotechnology companies, are relentlessly working to create a vaccine to eradicate the COVID-19 epidemic, which has hit millions of people and resulted in closures that have caused enormous damage to the world economy.

Pfizer and its German-based partner, BioNTech, demonstrated 95% efficacy in the final analysis of the mRNA-based vaccine candidate, BNT162b2. Companies have already applied to the FDA for an Emergency Use Permit (“EUA”). Pfizer / BioNTech is closely followed by Moderna. Moderna reported an efficiency ratio of 94.5% in III. From a first interim analysis of a phase-in study evaluating the coronavirus vaccine candidate, mRNA-1273, and is expected to report final data by the end of the month. The candidate is also expected to obtain the EUA by mid-December. Another nearby racer is AstraZeneca’s candidate, AZD1222.

While millions of doses of coronavirus vaccine are expected to be available next year with the strong manufacturing capabilities of Pfizer and Moderna, the need for billions of doses worldwide is likely to create opportunities for other vaccine producers who are currently lagging behind the competition. Here, we discuss four small biotechnology companies that are developing a coronavirus vaccine that could win in the coming months.

Inovio Pharmaceuticals Inc. I DO NOT

The company joined the coronavirus vaccine development competition in early March. However, the FDA’s partial withholding in September II / III. He hindered progress due to a phase study. The company is developing a DNA vaccine candidate, INO-4800, to fight SARS-CoV-2. Earlier this month, however, the FDA removed its partial withholding of Study II. From the section. The study III. The partial withholding of this section will be lifted after questions are raised about the Cellectra device for DNA vaccine administration. In addition, both phases of the study are being funded by the U.S. Department of Defense, suggesting that the funding accident will not continue.

The company’s shares have risen 214.8% so far this year.

Inovio Pharmaceuticals, Inc. price

Inovio Pharmaceuticals, Inc. price
Inovio Pharmaceuticals, Inc. price

Price of Inovio Pharmaceuticals, Inc. | Inovio Pharmaceuticals, Inc. Quote

Novavax, Inc. NVAX

The company’s coronavirus vaccine candidate, NVX-CoV2373, was awarded the Fast Track mark by the FDA earlier this month. The designation will help the company review its potential regulatory application for FDA approval / EUA more quickly. The company is already in the UK in a III. Phase investigation of the candidate. Interim data for the study are expected by the beginning of the first quarter of 2021. The late-stage study is expected to begin by the end of November. The clinical trials are being conducted by the company, with nearly $ 2 billion in funding received from various sources, including the U.S. government. The company has entered into several supply agreements with various countries for the NVX-CoV2373, which are already in effect.

Shares of Novavax were up 2477.9% this year.

Novavax, Inc. price

Novavax, Inc. price
Novavax, Inc. price

Price of Novavax, Inc. | Novavax, Inc. Quote

Translate Bio, Inc. TBIO

Although the company has lagged behind the competition for vaccines against the coronavirus, it has a strong partner in Sanofi. Last month, the company and its partner announced promising preclinical data about their coronavirus vaccine candidate, MRT5500. I / II. Phase study is expected to begin in the first quarter of 2021. The early-stage nature of vaccine development is likely to provide an opportunity to increase its share price upon reading potential positive test data and initiating advanced testing.

Shares of Translate Bio gained 124% this year.

Translate Bio, Inc. Price

Translate Bio, Inc. Price
Translate Bio, Inc. Price

Price of Bio, Inc. | Translate Bio, Inc. Quote

Vaxart, Inc. VXRT

Another company with an early-stage coronavirus vaccine candidate in its portfolio. The company began a phase I study in October with its oral tablet vaccine candidate, VXA-CoV2-1. The first clinical data from the study are expected in the coming weeks. Positive data should lead to higher stock prices. Preclinical data showed that the vaccine was able to generate both immune responses and a strong mucosal immune response against SARS-CoV-2. Please note that the company’s candidate is part of the U.S. Government’s Operation Warp Speed ​​(OWS) program and will receive funding for its clinical development.

Shares of Vaxart have risen 1726% so far this year. The company holds Zacks 3rd place (Hold). You can see A complete list of today’s Zacks # 1 Rank (Strong Buy) shares can be found here.




Are you looking for skyrocketing stocks?

Zacks recently released a special report on the growing investment opportunities in legal marijuana.

The industry, ignited by referendums and legislation, is expected to explode from an already robust $ 17.7 billion in 2019 to a staggering $ 73.6 billion by 2027. Early investors claim murder, but they need to be ready to act and know where to look.

Check out the pot stocks we are targeting >>

Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best shares for the next 30 days. Click to receive this free report

Novavax, Inc. (NVAX): Free stock analysis report

Bio, Inc. (TBIO) Translation: Free Stock Analysis Report

Inovio Pharmaceuticals, Inc. (INO): Free inventory analysis report

VAXART, INC. (VXRT): Free stock analysis report

Click here to read the article on Zacks.com.

Zacks investment research